摘要
慢性乙型肝炎目前还是不能治愈的疾病,主要原因是由于干扰素和核苷(酸)类似物等抗病毒药物不能有效清除肝细胞内乙型肝炎病毒共价闭合环状DNA(hepatitis B virus covalently closed circular DNA,HBV c c c D N A),导致药物疗效不佳或治疗后复发.因此,进一步加强对HBV感染的基础和临床研究,以清除肝细胞内HBV ccc DNA为目标开发新药和探讨治疗策略是今后肝病研究领域的重要课题.本文从细胞、动物和临床研究水平,将近年来开展的影响HBV ccc DNA水平的多种药物和治疗方案进行综述,旨在为临床医师较为全面地了解清除HBV ccc DNA的研究现状提供参考.
Chronic hepatitis caused by hepatitis B virus（HBV） infection remains an incurable disease at present,which is mainly because the approved antiviral agents,such as interferon-alpha and nucleos（t）ide analogues,cannot effectively eradicate intrahepatic hepatitis B virus covalently closed circular DNA（cccDNA）.And thus a suboptimal efficacy of antiviral agents and relapse after therapy occur very commonly.Therefore,novel drugs and treatment strategies remain to be developed on the basis of further theoretical and clinical research of HBV infection to achieve the ultimate goal of eradication of HBV cccDNA in the future.In this paper,we discuss multiple agents and therapeutic regimens influencing cccDNA levels,in order to help clinicians comprehensively understand the present situation in the research of the clearance of HBV cccDNA.
出处
《世界华人消化杂志》
CAS
2015年第22期3495-3504,共10页
World Chinese Journal of Digestology
